• Skip to primary navigation
  • Skip to main content
  • Skip to footer
AKRN

AKRN

Scientific Consulting

  • Services
    • Clinical Services
    • Regulatory Services
    • Medical Writing
    • Clinical Data Management
    • Statistical Analysis and Reporting
    • Aesthetic Devices
    • COVID-19
  • Team
    • Who we are
    • Our team
    • Code of Ethics
    • Our history
    • Our Community
  • News
    • News
    • Resources
    • Social Network
  • Career Portal
  • Contact
  • English
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

What You Need to Know About the New ISO 14155:2020 Standard

August 4, 2020 by M Nyakern

New requirements in the ISO 14155 standard for Medical Device Clinical Investigations

The ISO 14155:2020 (Clinical investigation of medical devices for human subjects – Good Clinical Practice) is the third edition of this standard of reference for the design, conduct, recording, and reporting of medical device clinical studies. It provides guidance to manufacturers and clinical research professionals on how to implement Good Clinical Practice (GCP) for pre and post-market clinical investigations designed to determine the safety and performance of a medical device.

The ISO 14155 standard provides the general specifications and requirements for clinical investigations to:

  • Protect the rights, safety, and well-being of human subjects;
  • Ensure scientific conduct of the clinical investigation and credibility of the clinical investigation results;
  • Define the responsibilities of the sponsor and principal investigator;
  • Assist sponsors, investigators, ethics committees, regulatory authorities, and other bodies involved in the conformity assessment of medical devices.

In addition to ISO 14155, clinical investigations in Europe must comply with the Medical Device Directives (MDD) and from 26 May 2021 with the European Medical Device Regulation (MDR). Clinical investigations must further comply with relevant provisions of the EU General Data Protection Regulation (GDPR) 2016/679 the Declaration of Helsinki and applicable national laws.

What is new in the third edition?

The third edition of this standard introduces clarifications to facilitate compliance with other international standards, such as ICH-GCP. The main goal of these changes is to ensure that the standard keeps its global acceptance level. Conducting clinical studies according to GCP is important not only to collect high-quality data under ethical conditions but also to meet regulatory compliance in the European Union (EU) and the United States (US). The US Food and Drug Administration (FDA) recognizes the ISO14155 standard for medical device trials and accept clinical data collected outside the US, under the condition that ISO14155-GCP has been followed.

Perhaps the biggest update in ISO 14155:2020 is the strong emphasis on the role of clinical evidence, as presented in the European Medical Device Regulation (MDR), the application of ISO 14971 risk management principles across all stages of clinical investigations, and the improved guidance on clinical study design.

The previous version of ISO 14155 only makes reference to ISO 14971 in terms of “investigational device risks”, and to support risk-benefit assessments to meet clinical investigation design rationale requirements. The new 2020 version adds “clinical risk management” to the list of sponsor responsibilities, which introduces the concept of clinical quality management processes and requires sponsor’s implementation and oversight, even if this task is outsourced to a third-party clinical research organization (CRO). 

This new standard is 25 pages longer compared to its previous version (58 vs. 83 pages). It has a total of ten annexes (three additional annexes compared to the second edition); three of which are normative annexes and include requirements.  Some of the major changes are:

  • A summary of the GCP principles, aligned with ICH-GCP;
  • Reference to the registration of the clinical investigation in a publicly accessible database, such as clinicaltrials.gov
  • Guidance on risk-based monitoring and considerations when writing the monitoring plan;
  • Guidance on statistical considerations, in line with increasing requirements by notified bodies;
  • Guidance for Ethics Committees (a new annex);
  • Guidance on clinical investigation audits, in line with clinical quality management;
  • Reinforcement of risk management according to ISO 14971 throughout the entire process of a clinical investigation;
  • Requirements for specific medical expertise in the planning of clinical investigations.

The new edition also provides clarification on the applicability of GCP to different clinical development stages (early feasibility studies, pre-market clinical investigations, post-market studies, and registries). This will be valuable when writing the clinical development section of the Clinical Evaluation Plan (CEP) as required by the new European Medical Device Regulation (EU MDR 2017/745).

The standard is valid from the moment of its publication (July 2020) with no official transition period. Although the new ISO 14155 edition includes relevant clarifications and valuable guidance, it should not result in any major changes for sponsor and clinical research professionals already conducting clinical research trials in compliance with the second edition (ISO14155:2011). It will be important to make ensure compliance with the new standard when designing forthcoming MDR clinical strategies and clinical investigations. 

How to get the new ISO 14155 standard?

The ISO 14155:2020 standard is not free, but copyright and must be purchased from an ISO member.  Purchasing the standard (as PDF and e-Pub layout) will provide the clinical research team valuable tools to ensure appropriate compliance.

In any stage of the clinical development, from early feasibility studies and pre-market clinical investigations to post-market studies and registries, medical device manufacturers should comply with the ISO14155 standard to ensure ethical and scientific conduct of the investigation and credibility of the clinical study results.

Conducting a clinical investigation according to the ISO 14155:2020 standard provides a high level of protection for human research subjects and allows companies to perform international device trials that generate clinical data with high integrity that are accepted by regulatory agencies worldwide. Please take time to consult our website and let us know if you need help to plan and execute an ISO 14155 and EU MDR compliant clinical trial.

Share this article

Category iconClinical Trial,  ISO 14155,  MDD,  MDR,  Medical Devices

Request a free consultation

Our team will help you to find the best solution for your needs. Our medical device experience and clinical knowledge can help you plan, set up, and execute a clinical trial, or performance study, in an optimal way.

Footer

AKRN Spain

AKRN Scientific Consulting S.L.
Address: Calle de Fuerteventura 4 (office 1.8)
Office Park La Marina
Postal Code: ES-28703 Madrid
Phone: +34 910 25 81 40
VAT ID: ES-B87990925

Contact details

Contact email: contact@akrnconsulting.com
Office phone: +34 910 258 140
Office phone: +34 911 136 635
Go to contact

Content

  • Medical Device Consulting Services
  • Clinical Studies for Medical Devices
  • Medical Writing
  • MedTech Regulatory Services
  • Contact

Resources

  • Articles
  • Resources
  • Career Portal

Latest articles

  • Roadmap to CE marking for medical devices and IVDs
  • The quality management system according to ISO 13485
  • Safety reporting for clinical investigations under the MDR
  • AKRN joins NAMSA – world leading MedTech Contract Research Organization (CRO)
  • Performance Studies for SARS-CoV-2 IVD tests
  • Progressive roll-out of the IVDR: extended timelines for certain IVDs

AKRN Scientific Consulting S.L ha sido beneficiaria del Fondo Europeo de Desarrollo Regional cuyo objetivo es mejorar la competitividad de las Pymes y gracias al cual ha puesto en marcha un Plan de Marketing Digital Internacional con el objetivo de mejorar su posicionamiento online en mercados exteriores durante el año 2020. Para ello ha contado con el apoyo del Programa XPANDE DIGITAL de la Cámara de Comercio de Burgos.
“Una manera de hacer Europa”

AKRN Scientific Consulting S.L ha sido beneficiaria de la subvención de contratos de trabajo de la Comunidad de Madrid, cofinanciado por el Fondo Social Europeo y la Iniciativa de Empleo Juvenil, en el marco del Programa Operativo de Empleo Juvenil 2014-2020, gestionado por la Consejería de Economía, Empleo y Hacienda.

La empresa (AKRN Scientific Consulting S.L.) es beneficiaria del Programa “la Caixa” Empleo Joven de ayudas para el fomento de la contratación de personas jóvenes. Estas ayudas están cofinanciadas por el Programa Operativo de Empleo Juvenil / Iniciativa de Empleo Juvenil – Fondo Social Europeo y por la Fundación Bancaria “la Caixa”.

 

 

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Privacy policy – Cookie Policy – Legal Notice –  Copyright © 2022. All rights reserved. Return to top

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
AKRN

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy